Recent developments in artificial intelligence (AI) have captured the attention of the pharmaceutical industry, particularly during the upcoming AI in Drug Discovery summit. Fay Lin, PhD, senior editor at GEN, recently visited Seattle, where she engaged in AI-focused discussions and conducted an exclusive interview with Nobel laureate David Baker, PhD. This dialogue sheds light on the current realities and misconceptions surrounding AI’s role in de novo protein design, highlighting the balance between genuine progress and inflated expectations.
In parallel, groundbreaking research from the University of California, San Diego, has leveraged machine learning to identify gene networks amenable to targeting for the reprogramming of cancer stem cells. This innovative approach could pave the way for novel therapeutic strategies against colon cancer, as early studies suggest promising drug candidates. As AI continues to evolve, its integration into drug discovery and cancer treatment may redefine the landscape of pharmaceutical development, emphasizing the need for professionals in regulatory, QA/QC, and CMC roles to stay informed and adaptable.
Get started today with Solo access →
